Furthermore, the IDH mutation has also issued novel targeted therapeutic avenues, like the IDH enzymes dual inhibitor vorasidenib in IDH mutant glioma patients (double-blind phase 3 clinical trial). The gene discussed is IDH2; the disease is central nervous system cancer.